Oracle Corp. (Nasdaq: ORCL), Comcast Corp. (Nasdaq: CMCSA), Cytori Therapeutics Inc. (Nasdsaq: CYTX), Wal-Mart Stores Inc. (NYSE: WMT), Abbot Laboratories (NYSE: ABT) and GT Solar International Inc. (Nasdaq: SOLR).

Oracle Corp. (Nasdaq: ORCL) Stock Alert – Oracle Corp Sells $4.5B Debt

Oracle Corp. (Nasdaq: ORCL) sold $4.5 billion debt, said International Financing Review (IFR) –a Thomson Reuters unit. The sale includes $1.5 billion of 3.75% notes due 2014, $1.75 billion of 5.00% notes due 2019, and $1.25 billion of 6.125% notes due 2039.

Oracle is an enterprise software company that develops, manufactures, markets, distributes and services database and middleware software, as well as applications software that help organizations to manage their businesses.

Oracle is organized into two businesses: software and services. These businesses are further divided into five operating segments. Its software business consists of two operating segments, new software licenses, and software license updates and product support. Its services business consists of three operating segments, consulting, On Demand and education.

The company’s software business represented 80% of its total revenues and its services business represented 2o% of total revenues during the fiscal year ended May 31, 2008 (fiscal 2008).

In June 2008, the company announced the formation of a Global Business Unit focused on software applications for the health sciences industry.

In its recent chart, ORCL is trading at its higher Bollinger Bands range, a bullish condition signaling that the stock is strong relative to the recent price action. MACD reflects a bullish signal, with the indicator trending above its 9-day moving average signal line, indicating upwardly trending moving averages.

Comcast Corp. (Nasdaq: CMCSA) Stock Alert – Comcast Rolls Out Wireless Internet; First Major Cable Operator to Offer WiFi Outside of Hotspots

Comcast Corp. (Nasdaq: CMCSA) recently introduced its wireless broadband connection outside of WiFi hotspots, the first majot cable TV operator to offer this service.  Portland, Ore. will be the place of launch, with at least three more cities scheduled for service during the second half of 2009.

Comcast’s new service includes Internet access speeds of up to 4 megabits per second, faster than comparable, non-Wi-Fi services currently available.

Comcast’s wireless broadband enables surfers Internet access, which for many users, may be an attractive alternative to mobile Internet connection offerings from phone companies.

Unlike LTE technology used by the phones companies, Comcast will be the first operator to offer WiMax as a competing technology in the battle for the wireless space.

The largest U.S. cable operator plans installations in the cities of Philadelphia, Atlanta and Chicago.
The 4G network of Clearwaire Corp will carry the service, where it’s offered.  Currently, the Clearwire 4G network is available in Portland and Atlanta, with plans to deploy in Las Vegas, Chicago, Charlotte, N.C., Dallas-Fort Worth, Texas, Honolulu, Philadelphia and Seattle later this year.
Other areas will use Sprint Nextel Corp 3G network.
Comcast provides cable services, offering a variety of entertainment, information and communications services to residential and commercial customers. It operates in two segments: Cable and Programming.

In its recent chart, CMCSA is trading at its higher Bollinger Bands range, a bullish condition signaling that the stock is strong relative to the recent price action. MACD reflects a bullish signal, with the indicator trending above its 9-day moving average signal line, indicating upwardly trending moving averages.

Cytori Therapeutics Inc. (Nasdsaq: CYTX) Stock Alert – Cytori Therapeutics Lags Nasdaq from March Low

Since the March 9 closing low of 1,268.64, the Nasdaq has risen 44.6%, settling on Tuesday at 1,835.04, while Cytori Therapeutics Inc. (Nasdsaq: CYTX) has risen 39.4% from its March 9 low of $2.59 to close Tuesday at $3.61, underperforming the Nasdaq.
Mkt Cap $161.23M

P/E Ratio N/A

52-Wk Range $1.42 - $7.97

Avg. Daily Vol. 441,000

Cytori Therapeutics develops, manufactures and sells medical technologies to enable the practice of regenerative medicine. The company’s commercial activities are focused on cosmetic and reconstructive surgery in Europe and Asia-Pacific, and stem and regenerative cell banking (cell preservation) in worldwide. Its product pipeline includes the development of new treatments for cardiovascular disease, spinal disc degeneration, gastrointestinal disorders, liver and renal disease and pelvic health conditions.

The company’s Celution System family of products processes patients’ cells at the bedside in real time. During the year ended December 31, 2008, the Celution 800/CRS System was introduced into the European cosmetic and reconstructive surgery market through a network of medical distributors. The Celution 900/MB is marketed in Japan through its commercialization partner, Green Hospital Supply Inc.

In its recent chart, CYTX is trading below its lower Bollinger Bands range, a bearish condition signaling that the stock is weak relative to the recent price action. MACD reflects a bearish signal, with the indicator trending below its 9-day moving average signal line, indicating downwardly trending moving averages.

Wal-Mart Stores Inc. (NYSE: WMT) Stock Alert – Wal-Mart Supports Obama’s Employer-based Healthcare Plan

Wal-Mart Stores Inc. (NYSE: WMT) said it supports president Barack Obama’s initiative to mandate large employers to offer health insurance to workers.

“We are for an employer mandate which is fair and broad in its coverage,” stated a letter addressed to Obama and signed by Mike Duke, the CEO of Wal-Mart; Andy Stern, the president of Service Employees International Union (SEIU) and John Podesta, the CEO of the Center for American Progress.
Wal-Mart’s public statement comes as Obama advances his agenda to overhaul the nation’s $2.5 trillion per year healthcare system.  The president advocates a system that reduces costs and adds approximately 46 million uninsured onto the insured rolls, a top priority of his administration.  The Congress will handle the details, but he urges legislators to require large companies to provide coverage and to exempt small businesses from the plan.
Wal-Mart, the nation’s largest private employer, has undergone pubic relations efforts and real policy initiatives regarding health coverage to change a battered image following news stories and lawsuits a few years ago which accused the retail giant of depriving its workers access to affordable health insurance while burdening private hospitals with higher unpaid patient accounts.
Wal-Mart heavily promoted its healthcare policy by offering a popular $4 generic drug program to its workers, and in 2007, joining with the SEIU to push for universal healthcare for all Americans by 2012.
Wal-Mart said it supports Obama in his call for healthcare reform, which should include as many companies as possible while covering full-time as well as part-time employees.
“This choice will require employers to consider the trade-off of agreeing to a coverage mandate and additional taxes versus the promise of reduced health care cost increases,” it said.
Wal-Mart Stores Inc. operates retail stores in various formats worldwide. The company provides an assortment of merchandise and services. Wal-Mart operates in three business segments: Walmart U.S., International and Sam’s Club.

The company’s Walmart U.S. segment accounted for 63.7% of its net sales, during the fiscal year ended January 31, 2009, (fiscal 2009), and operates stores in three different formats in the United States, as well as Wal-Mart’s online retail operations, walmart.com.

In its recent chart, WMT is trading below its lower Bollinger Bands range, a bearish condition signaling that the stock is weak relative to the recent price action. MACD reflects a bearish signal, with the indicator trending below its 9-day moving average signal line, indicating downwardly trending moving averages.

Abbot Laboratories (NYSE: ABT) Stock Alert –  Abbott Set to Appeal $1.67B Patent Infringement Ruling

Abbot Laboratories (NYSE: ABT) said it plans to appeal a jury-awarded $1.67 billion patent infringement ruling in a case involving one Abbot’s wildly-succesful drugs, sold by the pharmaceutical to treat rheumatoid arthritis and other immune disorders.

A jury in the Eastern District of Texas found Abbot’s drug, Humira, violated a patent on Johnson & Johnson’s Remicade.  Both drugs treat arthritis by blocking inflammation-causing proteins.

Abbot plans to appeal the ruling.

“We’re confident we’ll prevail on appeal and thus we would not owe any damages,” Abbott spokesman Scott Stoffel said in an e-mail; Stoffel also said the company reiterates its guidance.
Analyst Jami Rubin of Goldman Sachs said the appeals process could take years, with a reduced or an eliminated award more likely.  Johnson & Johnson has not pushed for an injunction against Abbot, nor did the jury award Johnson & Johnson royalties on Humira sales.
Rubin said he believes the company could absorb the judgment if forced to settle the case today.
With revenues relating to Humira of $4.5 billion last year, the blockbuster drug represents the largest source of any other Abbot drug.  Abbot anticipates revenue of $5.4 billion from Humira next year.
Johnson & Johnson filed suit against Abbot in April 2007, claiming Abbot infringed on its Remicade patent.
Abbott Laboratories is engaged in the discovery, development, manufacture, and sale of a range of health care products.

The pharmaceutical operates through four business segments: Pharmaceutical Products, Nutritional Products, Diagnostic Products, and Vascular Products.  The Pharmaceutical Products segment’s products include a line of adult and pediatric pharmaceuticals manufactured, marketed and sold worldwide. The Diagnostic Products segment’s products include diagnostic systems and tests manufactured, marketed and sold worldwide to blood banks, hospitals, commercial laboratories. The Nutritional Products segment’s products include a line of pediatric and adult nutritional products manufactured, marketed, and sold worldwide. The Vascular Products segment’s products include a line of coronary, endovascular, and vessel closure devices manufactured, marketed and sold worldwide.

In its recent chart, ABT is trading at its higher Bollinger Bands range, a bullish condition signaling that the stock is strong relative to the recent price action. MACD reflects a bullish signal, with the indicator trending above its 9-day moving average signal line, indicating upwardly trending moving averages.

GT Solar International Inc. (Nasdaq: SOLR) Stock Alert – GT Solar Paces Nasdaq During Rebound

Since the March 9 closing low of 1,268.64, the Nasdaq has risen 44.6%, settling on Tuesday at 1,835.04, while GT Solar International Inc. (Nasdaq: SOLR) has risen 44.8% from its March 9 low of $3.68 to close Tuesday at $5.33, pacing the Nasdaq.
Mkt Cap $823.57M

P/E Ratio 9.27

52-Wk Range $0.88 - $17.00

Avg. Daily Vol. 1,417,000

GT Solar International Inc., through its subsidiaries, is a provider of specialized manufacturing equipment and services essential for the production of photovoltaic wafers, cells and modules and polysilicon.

The company’s principal products are directional solidification systems (DSS) units, and chemical vapor deposition (CVD) reactors and related equipment. DSS units are specialized furnaces used to melt polysilicon and cast multicrystalline ingots, from which solar wafers are made. CVD reactors are used to react gases at high temperatures and pressures to produce polysilicon, the key raw material used in solar cells. Its customers include several of the world’s largest solar companies, as well as companies in the chemical industry.

The company operates through two segments: photovoltaic business and polysilicon business.

In its recent chart, SOLR is trading below its lower Bollinger Bands range, a bearish condition signaling that the stock is weak relative to the recent price action. MACD reflects a bearish signal, with the indicator trending below its 9-day moving average signal line, indicating downwardly trending moving averages.

InvestorSoup.com Research Disclosure

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT OR WEB SITE. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice.
The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
Our newsletter and Web site have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any of the companies profiled based solely on information contained in our report. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.
Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing.
InvestorSoup.com is a Web site wholly owned by BlueWave Advisors, LLC. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. BlueWave Advisors LLC, its principal and/or its affiliates will hold positions in the company profiled and may buy or sell securities at any time without notice.
Information contained in our report will contain “forward looking statements” as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward looking statements. These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company’s most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements.
We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company’s plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company’s operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related sources which we believe to be reliable.
To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information).
We encourage you to invest carefully and read investment information available at the Web sites of the SEC at http://www.sec.gov and FINRA at http://www.finra.org.